Affiliations 

  • 1 Department of Medicine and Centre of Excellence for Research in AIDS (CERiA), Faculty of Medicine, University Malaya, Kuala Lumpur, Malaysia
  • 2 TREAT Asia/amfAR - The Foundation for AIDS Research, Bangkok, Thailand
  • 3 The Kirby Institute, UNSW Sydney, Australia
  • 4 HIV-NAT/ Thai Red Cross AIDS Research Centre, Bangkok and Center of Excellence in Tuberculosis, Faculty of Medicine, Chulalongkorn University, Chulalongkorn, Thailand
  • 5 Queen Elizabeth Hospital, Hong Kong SAR
  • 6 Research Institute for Tropical Medicine, Muntinlupa City, Philippines
  • 7 Division of Infectious Diseases, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea
AIDS, 2023 Apr 01;37(5):823-835.
PMID: 36728672 DOI: 10.1097/QAD.0000000000003474

Abstract

BACKGROUND: Depression and substance use (SU) disorders are prevalent among people with HIV (PWH) and impact health outcomes despite successful antiretroviral therapy (ART). We explored quality of life, functional ability and associated factors among PWH screened positive for depression and/or SU.

METHODS: This cross-sectional study recruited adult PWH during routine follow-up at five HIV clinical sites in the Asia-Pacific region. Participants were screened for depression using Patient Health Questionnaire-9 and SU using Alcohol, Smoking, and Substance Involvement Screening Test (ASSIST). Quality of life (QoL) was assessed with WHOQOL-HIV BREF and functional ability with World Health Organization Disability Assessment Schedule 2.0 (WHODAS 2.0). Factors associated with mean QoL and disability scores were analysed using linear regression.

RESULTS: Of 864 PWH enrolled, 753 screened positive for depression or SU. The median (interquartile range, IQR) age was 38 (31-47) years and 97% were on ART. Overall mean WHOQOL-HIV BREF and WHODAS scores indicated greater impairment with increasing depressive symptom severity and SU risk. In multivariate analysis, PWH reporting previous trauma/stress (difference = 2.7, 95% confidence interval [CI] 1.5-3.9, P  

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.